KYNTRA BIO, INC.KYNB

Market cap
$28.19M
P/E ratio
Dec 31,
2015
Dec 31,
2016
Dec 31,
2017
Dec 31,
2018
Dec 31,
2019
Dec 31,
2020
Dec 31,
2021
Dec 31,
2022
Dec 31,
2023
Dec 31,
2024
Net loss----86-77-189-290-294-284-48
Depreciation666711121010103
Finance Lease, Right-of-Use Asset, Amortization----10105100
Net accretion of premium and discount on investments---04-0-2-252
Unrealized loss on equity investments-------0---
Investment income in unconsolidated variable interest entity------1234
Loss on disposal of property and equipment-0--0-00-1-00-0-3
Stock-based compensation28323852667371665125
Acquired in-process research and development expenses--------25-
Dividend received from unconsolidated variable interest entity--------22
Accounts receivable, net2-5-255-3512-25-1-37
Inventories----7914112-22
Prepaid expenses and other current assets-1-120129-12310-52816
Operating lease right-of-use assets-------4-11-12-66
Other assets002-13-74-0-0-1
Accounts payable2-0-14-31816-1615
Accrued and other liabilities----18311691-50-94
Operating lease liabilities, current------1-14-13
Deferred revenues----5-504558-4-28-28
Accrued interest expense related to sale of future revenues---------2
Accrued interest for finance lease liabilities----0-0-00-00
Operating lease liabilities, non-current-------4-9-13-66
Other long-term liabilities422252-28-12-18-3-1
Net cash used in operating activities----76-7982-82-146-315-138
Purchases of property and equipment2198645430
Payment made for acquired in-process research and development asset------2535--
Proceeds from sale of property and equipment0-000--0-1
Purchases of available-for-sale securities------4841642529
Cash Acquired from Acquisition--------1-
Proceeds from sales of available-for-sale securities------477-
Proceeds from maturities of investments---5453745783284401134
Net cash provided by investing activities----522120452-42789154126
Proceeds from Issuance of Secured Debt--------74-
Cash paid for transaction costs for senior secured term loan facilities--------3-
Repayments of finance lease liabilities----12135000
Repayments of lease obligations---000000-
Cash paid for payroll taxes on restricted stock unit releases-381613117500
Proceeds From Sale Of Future Revenues Net Of Issuance Costs-------50--
Cash paid for transaction costs related to sale of future revenues-------1--
Proceeds from Issuance Initial Public Offering--------48-
Proceeds from Issuance of Common Stock13103530213813440
Net cash (used in) provided by financing activities---14-413-147123-0
Effect of exchange rate change on cash and cash equivalents----0-053-5-31
Net increase (decrease) in cash and cash equivalents----58437552-507-16-42-12
Non cash acquisition in Fortis---------22-
Interest payments00000000016
Capital Expenditures Incurred but Not yet Paid104001100-
Cash and cash equivalents of continuing operations---------50